Proceeds Purposes Cortexyme, which is developing novel therapeutics and diagnostics for Alzheimer’s disease and other neurodegenerative disorders, received a $500,000 investment from Dolby Family Ventures as part of $1 million in seed financing to fund their preclinical research.